• Webinar October 9, 2019

    Olink-sponsored Science/AAAS webinar – now available on-demand!

    Title: “Emerging liquid biopsy biomarkers: Predicting response and resistance to cancer immunotherapy”
    Original broadcast date: Wednesday, 9 October 2019

    Speakers:
    Genevieve Boland, M.D., Ph.D., FACS Massachusetts General HospitalBoston, MA
    Evert Jan Van Limbergen, M.D., Ph.D.Maastro Clinic Maastricht, The Netherlands

    During the webinar, the speakers will:

    • Explain how whole-plasma proteomic profiling in melanoma and non–small cell lung cancer (NSCLC) patients enables discovery of blood-based biomarkers to predict immunotherapy responses, including resistance and toxicity
    • Describe how changes in immune activation during immunotherapy and radiation could be tracked by differentially expressed plasma proteins
    • Clarify how proteomic and transcriptomic biomarkers along with tumor-based analyses can drive patient selection and provide clinically actionable information
    • Demonstrate the relationship of plasma biomarkers to overall survival and progression-free survival in patients with advanced melanoma undergoing immunotherapy
    • Answer viewer questions during the live broadcast.

    Register now to view the on demand recording – REGISTER NOW

    Please note that if you previously registered for the live event, the link above will take you to a page that also provides direct access to the recording.